Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Anti-aging stocks have not proven immune to poor market conditions that have plagued the broader biotech industry. The biotech industry remains hampered by the same bleak economic conditions as those affecting growth comp...
This is Catalyst – a new short-form video series that asks senior executives the questions investors want answered. Exclusively on Channelchek. Brian Culley, CEO of Lineage Cell Therapeutics provides an update on the company’s OpRegen program for the treatment of dry age-related ...
Recorded August 23, 2022. Lineage Cell Therapeutics CEO Brian Culley is joined by Noble Capital Markets Senior Research Analyst Robert LeBoyer for a Q & A session featuring questions asked by the live audience throughout the event. Read More >>
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today Brian M. Culley, Lineage’s Chief Executive Officer, will present at the H.C. Wainwright 2nd A...
Quarterly Revenues Include Revenue Recognition. Lineage Cell Reported a loss of $6.8 million or $(0.04) per share, in-line with our estimate of $4.6 million or $(0.03) per share. Progress on the OpRegen collaboration with Roche/Genentech accounted for revenue of $4.1 million out of $4.6 millio...
Image source: The Motley Fool. Lineage Cell Therapeutics, Inc. (NYSEMKT: LCTX) Q2 2022 Earnings Call Aug 11, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Lineage Cell Therapeutics, Inc. (LCTX) Q2 2022 Earnings Ca...
Start Time: 16:30 End Time: 17:18 Lineage Cell Therapeutics, Inc. (LCTX) Q2 2022 Earnings Conference Call August 11, 2022, 16:30 PM ET Company Participants Brian Culley - CEO and Interim CFO Gary Hogge - SVP, Clinical and Medical Affairs Ioana Hone - Head...
Lineage Cell Therapeutics press release ( NYSE: LCTX ): Q2 GAAP EPS of -$0.04. Revenue of $4.6M (+820.0% Y/Y). Cash, Cash Equivalents, and Marketable Securities of $72M as of June 30, 2022 expected to provide capital through Q2 2024 For further details see: L...
Advanced RG6501 (OpRegen ® ) Development in Partnership with Roche and Genentech Published OPC1 Phase 1/2a Clinical Study Results in Journal of Neurosurgery: Spine Completed Key Activities to Support Planned Regulatory Interactions for OPC1 and VAC2 ...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its second quarter 2022 financial and operating results on Thursday, August 11, 20...
News, Short Squeeze, Breakout and More Instantly...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the Company has been added as a member of the broad-market Russell 3000 ® Index, effective after...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the Company’s CEO, Brian M. Culley, will present at the 2024 BIO International Convention , on Tue...
Persons with Lived Experience Session Expanded to Include Michaela & Kyle Devins Clinical Session Expanded to Include Neuralink Preclinical Session Expanded to Include Axonis, Novoron, Sania & Rewire Medical Lineage Cell Therapeutics, Inc. (NYSE America...